tiprankstipranks
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
US Market
DNTH
Dianthus Therapeutics
RESEARCH TOOLSreports
Want to see DNTH full AI Analyst Report?

Dianthus Therapeutics (DNTH) Stock News & Sentiment

437 Followers
Dianthus Therapeutics: Best-in-Class C1s Antibody Claseprubart and Strong Execution Support Outperform Rating
Premium
Ratings
Dianthus Therapeutics: Best-in-Class C1s Antibody Claseprubart and Strong Execution Support Outperform Rating
20d ago
DNTH
Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating
Premium
Ratings
Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating
1M ago
DNTH
Dianthus Highlights Strong Cash Runway and Streamlined Trials
Premium
Company Announcements
Dianthus Highlights Strong Cash Runway and Streamlined Trials
2M ago
8K
DNTH
Dianthus Therapeutics Announces Major Public Equity Offering
Premium
Company Announcements
Dianthus Therapeutics Announces Major Public Equity Offering
2M ago
8K
DNTH
AI Integration Exposes Dianthus Therapeutics to Heightened Cyber, Privacy, and Reputational Risks
Premium
Company Announcements
AI Integration Exposes Dianthus Therapeutics to Heightened Cyber, Privacy, and Reputational Risks
2M ago
DNTH
Dianthus Advances Claseprubart With Positive Phase 3 Update
Premium
Company Announcements
Dianthus Advances Claseprubart With Positive Phase 3 Update
2M ago
8K
DNTH
Dianthus Therapeutics: Best-in-Class Complement Inhibitor Potential and Multiple 2026 Catalysts Support Buy Rating
Premium
Ratings
Dianthus Therapeutics: Best-in-Class Complement Inhibitor Potential and Multiple 2026 Catalysts Support Buy Rating
3M ago
DNTH
More DNTH News >

DNTH News on the Web

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
The Motley Fool
Neutral
Why Dianthus Therapeutics Stock Just Took Off
TipRanks News
Bullish
Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating
TipRanks News
Bullish
Dianthus initiated with an Outperform at Wolfe Research
TipRanks News
Bullish
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
The Motley Fool
Neutral
Wells Fargo Remains a Buy on Dianthus Therapeutics (DNTH)
TipRanks News
Bullish
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Zacks
Bullish
Dianthus Therapeutics Stock Jumps on Big Trial Win
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
DNTH
Sector Average
Media Buzz
This Week2 articles
Weekly Average3.25 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DNTH’s Media Buzz Sentiment?
2 articles about DNTH were published this week. In an average week, 3.25 articles are published.
    What is DNTH’s weekly average amount of articles?
    In an average week, 3.25 articles about DNTH are published.
      What is DNTH’s News Sentiment?
      100% of articles about DNTH were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week